UniQure has accused the agency of reversing its stance on AMT-130, but hopes to settle on the parameters of a new trial.
The Food and Drug Administration has concluded that an experimental treatment for Huntington’s disease developed by UniQure was not providing benefit for patients based on existing clinical data, a senior FDA official told STAT, explaining the agency... [355 chars]